HealthDay News — For patients with type 2 diabetes and high cardiovascular risk receiving usual care, the addition of liraglutide is associated with lower rates of development and progression of diabetic kidney disease, according to a study published in the New England Journal of Medicine.
Johannes F.E. Mann, MD, from the Friedrich Alexander University of Erlangen in Germany, and colleagues reported the prespecified renal outcomes of a randomized controlled trial involving patients with type 2 diabetes receiving usual care who were assigned to liraglutide or placebo. A total of 9340 patients were randomized and followed for a median of 3.84 years.
The researchers found that the renal outcome (composite of new-onset persistent macroalbuminuria, persistent doubling of the serum creatinine level, end-stage renal disease, or death due to renal disease) occurred in fewer participants in the liraglutide vs placebo group (268 of 4,668 vs 337 of 4672 patients; hazard ratio [HR], 0.78). This result was mainly driven by new onset of persistent macroalbuminuria, which occurred in 161 vs 215 patients in the liraglutide group vs placebo group (HR, 0.74). The rates of renal adverse events, including the rate of acute kidney injury, were similar in the groups.
“This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo,” the authors write.
Disclosures: The study was partially funded by Novo Nordisk, the manufacturer of liraglutide.
Mann JFE, Orsted DD, Brown-Frandsen K, et al; for the LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839-848